TheraBionic P1 device receives European regulatory approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

TheraBionic GmbH, a German company co-founded by Boris Pasche, director of the Wake Forest Baptist Comprehensive Cancer Center, and Alexandre Barbault, co-inventor of the TheraBionic technology, has received European regulatory approval for its TheraBionic P1 medical device for use in the treatment of advanced hepatocellular carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login